Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Universidades de Italia y América ofrecen una tecnología de tratamiento del Alzheimer y enfermedades neurodegenerativas bajo acuerdos de licencia

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIT20170821003
Publicado:
05/09/2017
Caducidad:
05/09/2018
Resumen:
Un grupo de investigación de universidades de Italia y América que trabajan en el campo de enfermedades neurodegenerativas busca socios industriales y compañías farmacéuticas interesadas en adquirir la licencia de un proceso para desarrollar nanopartículas funcionalizadas de óxido de cerio, aplicadas principalmente en el tratamiento del Alzheimer y otras enfermedades neurodegenerativas caracterizadas por estrés oxidativo. Las nanopartículas son sintetizadas por el método de microemulsión e incorporan grupos funcionales químicamente reactivos, por ejemplo, grupos de aminos en la superficie. El sistema produce efectos neurotróficos que retrasan el progreso del Alzheimer y otras enfermedades, como ha sido demostrado por resultados experimentales in vitro. La tecnología está protegida por dos patentes en Estados Unidos.

Details

Tittle:
Technology to treat Alzheimer´s and neurodegenerative diseases jointly developed by Italian and American Universities offered for license agreement
Summary:
A team of researchers from an Italian university and an American university operating in the field of neurodegenerative diseases is looking for industrial partners, pharmaceutical companies, interested in acquiring a license on the proposed technology related to a process to create functionalized cerium oxide nanoparticles, mainly applied to treatment of Alzheimer´s disease, but also for other neurodegenerative diseases, characterized by oxidative stress.
Description:
The inventors of this innovative technology are an Italo-American research group who focused their activity research in life, health and environmental sciences in the field of neuronal biology.
Alzheimer´s disease (AD) is a neurodegenerative disorder of central nervous system that causes cognitive degeneration and progressive dementia accompanied by neuropathologic lesions, characterized by the presence of senile plaques of beta-amyloid protein. Although the molecular mechanism causing the toxicity is not completely defined, a large amount of experimental data suggest that oxidative stress plays a crucial role in the neurodegeneration mediated by amyloid -Y-beta; protein. As is known, the oxide nanoparticles of cerium (NPC) are powerful self-healing scavengers of reactive oxygen species.
In this context, the team has developed a process to create functionalized cerium oxide nanoparticles. These nanoparticles allow a ligation of specific antibody against the human beta-amyloid protein (main component of the plaques) for the therapeutic use in vivo and in vitro research. The nanoparticles, based on cerium oxide, are synthesized by the method of the microemulsion and chemically reactive functional groups are introduced on them (e.g. amino groups which are introduced on the surface of the nanoparticles). These amino groups bind the specific antibody while preserving its biological activity. This system produces neurotrophic effects that slow the progression of AD and other neurodegenerative diseases, as demonstrated by experimental in vitro results.
This technology is protected by two patents in United States.
The university is looking for industrial partners, preferably pharmaceutical companies, for license agreement. The stage of development of the invention is a working prototype.
Advantages and Innovations:
The proposed formulation is currently applied to Alzheimer´s disease. By varying the bounding antibody, the proposal functionalization procedure is suitable to be used also for other neurodegenerative diseases, characterized by oxidative stress, such as: Parkinson´s disease; Huntington´s disease; Amyotrophic lateral sclerosis (ALS); progressive supranuclear palsy; frontotemporal dementia; Lewy bodydementias; Creutzfeldt-Jakob disease (CJD) Gerstmann-Sträussler-Scheinker Disease (GSS).
The advantages, in brief, are:
Continuous regeneration of the antioxidant action;
Antioxidant effectiveness, for a long time, with a single dosage;
Targeting of specific proteins with selectivity of neurodegeneration sites;
Treatment effectiveness: the disease is already in advanced stages of progression, at the onset of symptoms. The targeted use to singles areas of neurodegeneration of the cerium oxide nanoparticles allows to preserve neuronal function and fight the disease progression.
The system is non-invasive, it does not present toxicity in vitro, and the method of preparation is easily translatable to chemical-pharmaceutical industry with low production costs.
It is a starting point for a neurodegenerative disease therapy, in particular for those diseases without current therapies.
The method and the scaffold "nanoparticles" are potentially adaptable to targeting other neurodegenerative diseases, by the replacement of antibody.
Stage of Development:
Prototype available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Two US patent granted

Partner sought

Type and Role of Partner Sought:
Type of partner sought: SME, MNE

Specific area of activity of the partner: pharmaceutical companies. Biotech companies are also targeted.
Task to be performed by the partner sought: acquiring a license.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Italian

Keywords

Technology Keywords:
06002 Biología / biotecnología
06001016 Fisiología
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica